英文名称Anti-ADAM19/FITC 中文名称:FITC标记的去整合素样金属蛋白酶19抗体 别 名A disintegrin and metalloproteinase domain 19 (meltrin beta); A disintegrin and metalloproteinase domain 19; ADAM 19; ADAM metallopeptidase domain 19; Disintegrin and metalloproteinase domain containing protein 19; FKSG 34; FKSG34; MADDAM; Meltrin beta; ADA19_HUMAN; Metalloprotease and disintegrin dentritic antigen marker; MLTN B; MLTNB.
详细介绍:
规格:100ul
说 明 书100ul
研究领域细胞生物 免疫学 信号转导 细胞骨架 细胞外基质 泛素
抗体来源Rabbit
克隆类型Polyclonal
交叉反应 Human, Mouse, Rat, Pig,
产品应用IF=1:50-200
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量82kDa
性 状Lyophilized or Liquid
浓 度1mg/ml
免 疫 原KLH conjugated synthetic peptide derived from human ADAM19
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
相关资料:
产品介绍background:
This gene encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins and have been implicated in a variety of biological processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis. This member is a type I transmembrane protein and serves as a marker for dendritic cell differentiation. It has been demonstrated to be an active metalloproteinase, which may be involved in normal physiological processes such as cell migration, cell adhesion, cell-cell and cell-matrix interactions, and signal transduction. It is proposed to play a role in pathological processes, such as cancer, inflammatory diseases, renal diseases, and Alzheimer's disease. [provided by RefSeq, May 2013].